PMID- 32898723
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20231110
IS  - 1471-4973 (Electronic)
IS  - 1471-4892 (Print)
IS  - 1471-4892 (Linking)
VI  - 54
DP  - 2020 Oct
TI  - Contribution of the bone marrow stromal cells in mediating drug resistance in 
      hematopoietic tumors.
PG  - 36-43
LID - S1471-4892(20)30057-6 [pii]
LID - 10.1016/j.coph.2020.08.006 [doi]
AB  - The bone marrow microenvironment (BMM) provides input via production of 
      cytokines, chemokines, extracellular matrixes in the context of lower oxygen 
      levels that influences self-renewal, survival, differentiation, progression, and 
      therapeutic resistance of multiple myeloma and leukemic cells. Within the context 
      of the BMM, tumor cells are supported by osteoblasts, bone marrow stromal cells 
      (BMSCs), fibroblasts, myeloid cells, endothelial cells and blood vessels, as well 
      as extracellular matrix (ECM) that contribute to tumor progression. Environmental 
      mediated-drug resistance (EM-DR) contains cell adhesion-mediated drug resistance 
      (CAM-DR) and soluble factor-mediated drug resistance (SM-DR) that contributes to 
      de novo drug resistance. In this review, we focus on the crosstalk between the 
      BMM and tumor cells as well as mechanisms underlying the BMM contributing to drug 
      resistance in hematologic malignancies.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Chen, Wei-Chih
AU  - Chen WC
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia 
      University, Morgantown, WV 26506 USA; Cancer Center, West Virginia University, 
      Morgantown, WV 26506 USA.
FAU - Hu, Gangqing
AU  - Hu G
AD  - Cancer Center, West Virginia University, Morgantown, WV 26506 USA; Department of 
      Microbiology, Immunology and Cell Biology, School of Medicine, West Virginia 
      University, Morgantown, WV 26506 USA.
FAU - Hazlehurst, Lori A
AU  - Hazlehurst LA
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia 
      University, Morgantown, WV 26506 USA; Cancer Center, West Virginia University, 
      Morgantown, WV 26506 USA. Electronic address: lori.hazlehurst@hsc.wvu.edu.
LA  - eng
GR  - R01 CA195727/CA/NCI NIH HHS/United States
GR  - U54 GM104942/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200906
PL  - England
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
SB  - IM
MH  - Animals
MH  - Cell Adhesion
MH  - *Drug Resistance, Neoplasm/genetics
MH  - Epigenesis, Genetic
MH  - *Hematologic Neoplasms/drug therapy/genetics
MH  - Humans
MH  - *Mesenchymal Stem Cells/physiology
PMC - PMC7770000
MID - NIHMS1622797
COIS- Conflict of interest The author declare no conflict of interest.
EDAT- 2020/09/09 06:00
MHDA- 2021/10/12 06:00
PMCR- 2021/10/01
CRDT- 2020/09/08 20:08
PHST- 2020/06/09 00:00 [received]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
PHST- 2020/09/08 20:08 [entrez]
PHST- 2021/10/01 00:00 [pmc-release]
AID - S1471-4892(20)30057-6 [pii]
AID - 10.1016/j.coph.2020.08.006 [doi]
PST - ppublish
SO  - Curr Opin Pharmacol. 2020 Oct;54:36-43. doi: 10.1016/j.coph.2020.08.006. Epub 
      2020 Sep 6.